Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
39.29
-0.39 (-0.98%)
Mar 9, 2026, 3:06 PM EDT - Market open
Company Description
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 182 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 100 Marine Parkway, Suite 400 Redwood City, California 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | Chairman, President, Chief Executive Officer and Chief Operating Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Jesse Schumaker | General Counsel |
| Lauren Budesheim | Senior Vice President of People |
| Kristen Yen M.S. | Senior Vice President of Global Clinical Operations and Patient Advocacy |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of New Product Planning |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Mitchell Nagao M.B.A., Pharm.D. | Senior Vice President of Medical Affairs |
| Dr. Dairine Dempsey Ph.D. | Senior Vice President of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 8-K | Current Report |
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Jan 23, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |